Global Biopharma Buffer Market Research Report 2023

Publication ID:

PB510233023

Publication Date:

October 19, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

A buffer solution is comprised of a weak conjugate acid-base pair, for example, a weak acid and its conjugate base, or a weak base and its conjugate acid. Small quantities of other acids or bases are neutralized when added to the solution, and as a result, the solution resists changes in pH. Solutions with stable pH are required for the processing of protein-based biologic APIs because of their sensitivity to changes in pH. The stable pH range and capacity (the amount of acid/base that can be added without a change in pH) of a buffer are determined by the conjugate acid-base pair.
Most purification steps for downstream processing of biologics require buffers to equilibrate, condition, wash, elute, or concentrate the product. They are used in product isolation and purification steps to facilitate protein capture and polishing and also in the filtration process for the removal of viruses or depyrogenation. Aqueous solutions are also required for cleaning and disinfecting downstream processing equipment, such as chromatography matrices and membrane filtration systems. The main equipment involved in downstream processing with buffers includes mixers for buffer preparation, as well as equipment for purification, including packed-bed chromatography systems, fluidized beds, ultrafiltration and diafiltration membranes, microfiltration membranes, depth filtration cartridges, and virus-removal systems.
The global Biopharma Buffer market is projected to reach US$ 1068.2 million in 2029, increasing from US$ 841 million in 2022, with the CAGR of 3.4% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Biopharma Buffer 91制片厂.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Biopharma Buffer market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Avantor
Alfa Aesar (Thermo Fisher)
Merck
Lonza
Bio-Rad
BD
GE Healthcare
Promega Corporation
Hamilton Company
XZL BIO-TECHNOLOGY
SRL
Segment by Type
Phosphates Type
Acetates Type
TRIS Type
Others
Segment by Application
Research Institution
Pharmaceutical Industry
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Biopharma Buffer report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers鈥� Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers鈥� Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Biopharma Buffer Market Overview
1.1 Product Overview and Scope of Biopharma Buffer
1.2 Biopharma Buffer Segment by Type
1.2.1 Global Biopharma Buffer Market Value Comparison by Type (2023-2029)
1.2.2 Phosphates Type
1.2.3 Acetates Type
1.2.4 TRIS Type
1.2.5 Others
1.3 Biopharma Buffer Segment by Application
1.3.1 Global Biopharma Buffer Market Value by Application: (2023-2029)
1.3.2 Research Institution
1.3.3 Pharmaceutical Industry
1.3.4 Others
1.4 Global Biopharma Buffer Market Size Estimates and Forecasts
1.4.1 Global Biopharma Buffer Revenue 2018-2029
1.4.2 Global Biopharma Buffer Sales 2018-2029
1.4.3 Global Biopharma Buffer Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Biopharma Buffer Market Competition by Manufacturers
2.1 Global Biopharma Buffer Sales Market Share by Manufacturers (2018-2023)
2.2 Global Biopharma Buffer Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Biopharma Buffer Average Price by Manufacturers (2018-2023)
2.4 Global Biopharma Buffer Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Biopharma Buffer, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Biopharma Buffer, Product Type & Application
2.7 Biopharma Buffer Market Competitive Situation and Trends
2.7.1 Biopharma Buffer Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Biopharma Buffer Players Market Share by Revenue
2.7.3 Global Biopharma Buffer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Biopharma Buffer Retrospective Market Scenario by Region
3.1 Global Biopharma Buffer Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Biopharma Buffer Global Biopharma Buffer Sales by Region: 2018-2029
3.2.1 Global Biopharma Buffer Sales by Region: 2018-2023
3.2.2 Global Biopharma Buffer Sales by Region: 2024-2029
3.3 Global Biopharma Buffer Global Biopharma Buffer Revenue by Region: 2018-2029
3.3.1 Global Biopharma Buffer Revenue by Region: 2018-2023
3.3.2 Global Biopharma Buffer Revenue by Region: 2024-2029
3.4 North America Biopharma Buffer Market Facts & Figures by Country
3.4.1 North America Biopharma Buffer Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Biopharma Buffer Sales by Country (2018-2029)
3.4.3 North America Biopharma Buffer Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Biopharma Buffer Market Facts & Figures by Country
3.5.1 Europe Biopharma Buffer Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Biopharma Buffer Sales by Country (2018-2029)
3.5.3 Europe Biopharma Buffer Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Biopharma Buffer Market Facts & Figures by Country
3.6.1 Asia Pacific Biopharma Buffer Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Biopharma Buffer Sales by Country (2018-2029)
3.6.3 Asia Pacific Biopharma Buffer Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Biopharma Buffer Market Facts & Figures by Country
3.7.1 Latin America Biopharma Buffer Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Biopharma Buffer Sales by Country (2018-2029)
3.7.3 Latin America Biopharma Buffer Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Biopharma Buffer Market Facts & Figures by Country
3.8.1 Middle East and Africa Biopharma Buffer Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Biopharma Buffer Sales by Country (2018-2029)
3.8.3 Middle East and Africa Biopharma Buffer Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Biopharma Buffer Sales by Type (2018-2029)
4.1.1 Global Biopharma Buffer Sales by Type (2018-2023)
4.1.2 Global Biopharma Buffer Sales by Type (2024-2029)
4.1.3 Global Biopharma Buffer Sales Market Share by Type (2018-2029)
4.2 Global Biopharma Buffer Revenue by Type (2018-2029)
4.2.1 Global Biopharma Buffer Revenue by Type (2018-2023)
4.2.2 Global Biopharma Buffer Revenue by Type (2024-2029)
4.2.3 Global Biopharma Buffer Revenue Market Share by Type (2018-2029)
4.3 Global Biopharma Buffer Price by Type (2018-2029)
5 Segment by Application
5.1 Global Biopharma Buffer Sales by Application (2018-2029)
5.1.1 Global Biopharma Buffer Sales by Application (2018-2023)
5.1.2 Global Biopharma Buffer Sales by Application (2024-2029)
5.1.3 Global Biopharma Buffer Sales Market Share by Application (2018-2029)
5.2 Global Biopharma Buffer Revenue by Application (2018-2029)
5.2.1 Global Biopharma Buffer Revenue by Application (2018-2023)
5.2.2 Global Biopharma Buffer Revenue by Application (2024-2029)
5.2.3 Global Biopharma Buffer Revenue Market Share by Application (2018-2029)
5.3 Global Biopharma Buffer Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Avantor
6.1.1 Avantor Corporation Information
6.1.2 Avantor Description and Business Overview
6.1.3 Avantor Biopharma Buffer Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Avantor Biopharma Buffer Product Portfolio
6.1.5 Avantor Recent Developments/Updates
6.2 Alfa Aesar (Thermo Fisher)
6.2.1 Alfa Aesar (Thermo Fisher) Corporation Information
6.2.2 Alfa Aesar (Thermo Fisher) Description and Business Overview
6.2.3 Alfa Aesar (Thermo Fisher) Biopharma Buffer Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Alfa Aesar (Thermo Fisher) Biopharma Buffer Product Portfolio
6.2.5 Alfa Aesar (Thermo Fisher) Recent Developments/Updates
6.3 Merck
6.3.1 Merck Corporation Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Biopharma Buffer Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Merck Biopharma Buffer Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 Lonza
6.4.1 Lonza Corporation Information
6.4.2 Lonza Description and Business Overview
6.4.3 Lonza Biopharma Buffer Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Lonza Biopharma Buffer Product Portfolio
6.4.5 Lonza Recent Developments/Updates
6.5 Bio-Rad
6.5.1 Bio-Rad Corporation Information
6.5.2 Bio-Rad Description and Business Overview
6.5.3 Bio-Rad Biopharma Buffer Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Bio-Rad Biopharma Buffer Product Portfolio
6.5.5 Bio-Rad Recent Developments/Updates
6.6 BD
6.6.1 BD Corporation Information
6.6.2 BD Description and Business Overview
6.6.3 BD Biopharma Buffer Sales, Revenue and Gross Margin (2018-2023)
6.6.4 BD Biopharma Buffer Product Portfolio
6.6.5 BD Recent Developments/Updates
6.7 GE Healthcare
6.6.1 GE Healthcare Corporation Information
6.6.2 GE Healthcare Description and Business Overview
6.6.3 GE Healthcare Biopharma Buffer Sales, Revenue and Gross Margin (2018-2023)
6.4.4 GE Healthcare Biopharma Buffer Product Portfolio
6.7.5 GE Healthcare Recent Developments/Updates
6.8 Promega Corporation
6.8.1 Promega Corporation Corporation Information
6.8.2 Promega Corporation Description and Business Overview
6.8.3 Promega Corporation Biopharma Buffer Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Promega Corporation Biopharma Buffer Product Portfolio
6.8.5 Promega Corporation Recent Developments/Updates
6.9 Hamilton Company
6.9.1 Hamilton Company Corporation Information
6.9.2 Hamilton Company Description and Business Overview
6.9.3 Hamilton Company Biopharma Buffer Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Hamilton Company Biopharma Buffer Product Portfolio
6.9.5 Hamilton Company Recent Developments/Updates
6.10 XZL BIO-TECHNOLOGY
6.10.1 XZL BIO-TECHNOLOGY Corporation Information
6.10.2 XZL BIO-TECHNOLOGY Description and Business Overview
6.10.3 XZL BIO-TECHNOLOGY Biopharma Buffer Sales, Revenue and Gross Margin (2018-2023)
6.10.4 XZL BIO-TECHNOLOGY Biopharma Buffer Product Portfolio
6.10.5 XZL BIO-TECHNOLOGY Recent Developments/Updates
6.11 SRL
6.11.1 SRL Corporation Information
6.11.2 SRL Biopharma Buffer Description and Business Overview
6.11.3 SRL Biopharma Buffer Sales, Revenue and Gross Margin (2018-2023)
6.11.4 SRL Biopharma Buffer Product Portfolio
6.11.5 SRL Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Biopharma Buffer Industry Chain Analysis
7.2 Biopharma Buffer Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Biopharma Buffer Production Mode & Process
7.4 Biopharma Buffer Sales and Marketing
7.4.1 Biopharma Buffer Sales Channels
7.4.2 Biopharma Buffer Distributors
7.5 Biopharma Buffer Customers
8 Biopharma Buffer Market Dynamics
8.1 Biopharma Buffer Industry Trends
8.2 Biopharma Buffer Market Drivers
8.3 Biopharma Buffer Market Challenges
8.4 Biopharma Buffer Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Avantor
Alfa Aesar (Thermo Fisher)
Merck
Lonza
Bio-Rad
BD
GE Healthcare
Promega Corporation
Hamilton Company
XZL BIO-TECHNOLOGY
SRL

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.